Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 7Small Cell Lung Carcinoma 5Neoplasms 4Carcinoma, Hepatocellular 4Carcinoma 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Cholangiocarcinoma 3Neoplasms by Site 2Neoplasms by Histologic Type 2Liver Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1Mouth Neoplasms 1Liver Diseases 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Gemcitabine 19130-nm albumin-bound paclitaxel 16Specimen Handling 15Magnetic Resonance Spectroscopy 10Irinotecan 10Fluorouracil 9Biopsy 9Leucovorin 8pembrolizumab 7Oxaliplatin 7Cyclophosphamide 7fludarabine 6Cisplatin 5Pemetrexed 4Cetuximab 4Albumin-Bound Paclitaxel 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3durvalumab 3dehydroftorafur 3aldesleukin 3Taxes 3Radiosurgery 3Nivolumab 3Immunoglobulin G 3Disulfides 3Carboplatin 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × durvalumab × 30 days × Clear all
NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT05411094 2026-05-29

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡